SCHEMBL5750322

SCHEMBL5750322

CSc1cccc(Oc2ncccc2C(=O)NC2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.59
CNR2 P34972 4/20 0.54
CNR1 P21554 3/20 0.54
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.52
HTT P42858 1/20 0.51
GAA P10253 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HSD11B1 P28845 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5753703 0.91 RAB9A (0.47) RAB9ACNR2CNR1ALDH1A1MEN1
SCHEMBL5753712 0.91 RAB9A (0.47) RAB9ACNR2CNR1ALDH1A1MEN1
SCHEMBL8319888 0.90 RAB9A (0.47) RAB9ACNR2CNR1ALDH1A1MEN1
Hydrochloric Acid SCHEMBL5751698 0.89 RAB9A (0.46) RAB9ACNR2CNR1ALDH1A1MEN1
Hydrochloric Acid SCHEMBL5751702 0.89 RAB9A (0.46) RAB9ACNR2CNR1ALDH1A1MEN1
SCHEMBL5840316 0.89 CNR2 (0.48) RAB9ACNR2CNR1ALDH1A1HPGD
SCHEMBL5841455 0.88 RAB9A (0.49) RAB9ACNR2CNR1ALDH1A1SMN1; SMN2
SCHEMBL5748277 0.87 CHRM1 (0.44) RAB9ACNR2CNR1ALDH1A1
SCHEMBL5750939 0.87 CHRM1 (0.44) RAB9ACNR2CNR1ALDH1A1
SCHEMBL8312805 0.87 PDE4B (0.44) RAB9ACNR2CNR1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141586-B2 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. (US) 2006-11-28 US disclosed
EP-1651609-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS Pfizer Limited (GB) 2006-05-03 EP disclosed
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC. 2005-02-10 US disclosed
WO-2005009966-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed
WO-2005009966-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032838-A1 Nicotinamide derivatives useful as PDE4 inhibitors CBR3, CBR1, PDE9A RAB9A 1016/4885CNR2 88/4885CNR1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.